The approval is supported by data from the phase 3 VOLGA trial.
|Videos|September 28, 2020
Disposable ureteroscope reduces costs of care
Author(s)Urology Times staff
Amy E. Krambeck, MD, discusses the findings of a recent 90-day trial of a single-use disposable ureteroscope.
Advertisement
Amy E. Krambeck, MD, discusses a recent Urology Practice paper, "Initial Experience With a Novel Single Use Disposable Ureteroscopy: A Prospective Single Arm 90-day Trial of the Axis Ureteroscope," for which she served as a study author. Krambeck is the Michael O. Koch Professor of Urology at Indiana University School of Medicine, Indianapolis.
Advertisement
Related to this article
Jessica Rett, PhD, joins Adam B. Weiner, MD, to discuss how medical terminology and common metaphors shape patient understanding and communication in cancer care.
The recommendation is backed by data from the phase 3 LITESPARK-011 trial.
Aaron Berger, MD, discusses testosterone recovery after prostate cancer therapy interruption and its implications for quality of life, PSA kinetics, and treatment decisions.
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
4
Q&A: Where ProACT fits in the male stress urinary incontinence algorithm
5